Targeted Molecular Diagnostics (TMD), an advanced, oncology focused, specialty laboratory that specializes in the application of molecular pathology, today announced that the September 2004 issue of The British Journal of Cancer (91(6):1190-4), co-authored by Dr. Sarah Bacus, President and Chief Scientist Officer at TMD, published the results of a prospective study showing that the efficacy of Herceptin therapy is influenced by several factors that include the expression of erbB receptors in addition to Herceptin’s biological target, erbB2, ligands for erbB receptors and the activation of downstream signaling proteins.
